This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary DNA Virus Infection Diagnostics Development
BioVenic provides in vitro diagnostics development for veterinary DNA virus infections, supporting the creation of accurate diagnostic assays for DNA viruses affecting companion animals (dogs, cats), livestock (pigs, cattle, sheep), and poultry (chickens, ducks). Our platform covers both immunodiagnostic and molecular diagnostic approaches, delivering specialized assays and techniques that heighten the precision and efficacy of DNA virus detection. We support tailored diagnostic programs with comprehensive guidance throughout the development process, reducing false-negative/false-positive risk and turnaround time to improve animal welfare.
Significance of Formulating Solutions for Veterinary DNA Virus Infection Diagnostics ▼
Veterinary DNA Virus Infection Diagnostics Development Services
BioVenic channels unwavering commitment to propelling the DNA virus detection domain, meticulously steering through robust research and collaboration with leading experts. Our distinct service is tailored to drive the field's advancement by spearheading the creation of specialized diagnostic assays and techniques. These innovations heighten the precision and efficacy of DNA virus detection. Our comprehensive suite of services encompasses veterinary diagnostic solutions harnessed from both the immunodiagnostic and molecular diagnostic realms. This multifaceted approach underscores our dedication to pioneering progress within veterinary DNA virus infection diagnostics.
Common DNA Viruses for Veterinary Diagnostics Development
BioVenic specializes in identifying veterinary viruses and developing veterinary diagnostics covering various DNA virus species that impact animals, including companion animals like dogs and cats, livestock animals like pigs, cattle, and sheep, and poultry such as chickens and ducks. ▼
Our Service Flow Chart
Related Research
To enable rapid and on-site diagnosis of African swine fever virus (ASFV) without complex laboratory infrastructure, a clinical validation study established and evaluated DNA extraction-free real-time PCR (qPCR), visual loop-mediated isothermal amplification (LAMP), and fluorescent LAMP assays. Designed with primers and probes targeting conserved regions to cover all 24 ASFV genotypes, all three extraction-free detection platforms, alongside the standard World Organisation for Animal Health (OIE) qPCR, demonstrated an identical analytical limit of detection (LOD) of 5.8 copies/μL using plasmid reference materials. Across 100 swine clinical samples (including blood and tissues such as spleen, lymph nodes, and kidney), all three assays exhibited 100% diagnostic specificity without cross-reactivity against common swine pathogens including CSFV, PRRSV, PCV, PPV, and PRV. The DNA extraction-free qPCR achieved perfect diagnostic sensitivity (100%) and concordance (Cohen's kappa = 1.0) compared to the reference OIE qPCR protocol. Meanwhile, the visual and fluorescent LAMP assays yielded diagnostic sensitivities of 87.1% and 90.32% with kappa coefficients of 0.84 and 0.88, respectively.
Fig. 1 Specificity of ASFV detection by DNA extraction-free qPCR, visual LAMP and fluorescent LAMP, and OIE qPCR.1
Why Choose Us?
Our solutions are tailored to the specific needs of our customers and provide comprehensive support and guidance throughout the diagnostic process.
We leverage our extensive experience in diagnostic development to ensure reliable and accurate testing, reducing the risk of false negative or false positive results.
Our expertise in DNA virus diagnostics reduces turnaround time, allowing veterinarians to quickly diagnose and initiate appropriate treatment.
Case Study: Viral Load-Based Detection of a DNA Virus in Companion Animals
BioVenic developed a custom probe-based qPCR assay—from conserved viral target selection through assay optimization to supply of a ready-to-use kit with internal controls—and evaluated matched oropharyngeal swab, whole blood, and fecal samples from infected animals. As shown in the figure, virus levels differed clearly across sample types: fecal samples carried by far the highest viral load, followed by whole blood, while oropharyngeal swabs remained positive at lower levels.
Fig. 2 Viral Load of The Target DNA Virus by Sample Type
Frequently Asked Questions
Q1: What types of samples can be used for developing DNA virus diagnostics, and what are the shipping requirements?
A: We accept a wide range of biological specimens, including whole blood, serum, plasma, tissue biopsies, nasal or rectal swabs, and bodily fluids depending on the target DNA virus and host species. Samples should be collected using appropriate sterile techniques and stored in virus transport media (VTM) or nucleic acid preservation buffers. To ensure nucleic acid integrity, specimens generally require cold-chain transport, such as shipping on dry ice. Because optimal sample volume and preservation conditions vary by target virus and assay platform, please consult our technical support team for specific sample preparation guidelines prior to shipment.
Q2: Which diagnostic platforms can BioVenic develop for veterinary DNA viral detection?
A: Our technical team supports end-to-end development across multiple assay formats tailored to your target application. These include molecular diagnostics such as PCR, quantitative real-time PCR (qPCR), digital PCR (dPCR), and isothermal amplification techniques (e.g., LAMP, RPA). Additionally, we develop immunodiagnostic platforms, including lateral flow immunoassay (LFIA) strips for point-of-care testing and enzyme-linked immunosorbent assays (ELISA) for high-throughput screening. We can also integrate modern biosensors or microfluidic chips. If you have specific sensitivity, specificity, or multiplexing requirements, we encourage you to discuss your project parameters with our technical specialists to choose the ideal platform.
Q3: How do you handle viral sequence variations and high-risk pathogen safety in diagnostic assay design?
A: We utilize advanced bioinformatic pipelines to analyze viral genome databases, targeting highly conserved regions of the DNA virus to prevent false negatives caused by genetic mutations or strain variations. For high-consequence or regulated animal pathogens, we operate under strict biosafety management protocols and regulatory guidelines. Depending on the pathogen's risk level, we can work with synthetic target sequences, recombinant viral proteins, or inactivated viral matrices to ensure complete safety throughout the development workflow. For specific pathogen handling capabilities and compliance details, please reach out to our technical support staff.
Q4: What is the typical workflow and timeline for a custom diagnostic development project?
A: A standard project begins with target selection and bioinformatic primer/probe or antigen/antibody design, followed by assay optimization, analytical validation, and clinical sample testing. The timeline usually ranges from a few weeks to several months, depending on the complexity of the platform, the availability of target biological reagents, and whether multiplex detection is required. We provide custom milestones and regular progress reports throughout the process. Since timeframes depend heavily on specific assay performance goals and validation scales, we recommend contacting our technical support team to receive a detailed project timeline and custom proposal.
BioVenic handles all your animal DNA virus in vitro diagnostics development needs, and we are ready to work with you to improve animal welfare. Should you have any questions or require further information, we encourage you to contact us without hesitation.
Reference
- Yang, Lili, et al. "Clinical validation of DNA extraction-free qPCR, visual LAMP, and fluorescent LAMP assays for the rapid detection of African swine fever virus." Life 12.7 (2022): 1067. https://doi.org/10.3390/life12071067. Used under CC BY 4.0. Without modification.